A Phase II, Open-Label, Single-Arm Study of INCMGA00012 and Telotristat Ethyl in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Latest Information Update: 30 Sep 2021
At a glance
- Drugs Retifanlimab (Primary) ; Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine tumours
- Focus Therapeutic Use
- 23 Sep 2021 Planned End Date changed from 30 Jun 2021 to 2 Sep 2021.
- 23 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 2 Sep 2021.
- 23 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.